Lawrence G. Hamel, Chief Development Officer at ACELRX PHARMACEUTICALS INC (ACRX), sold 6,953 shares at $4.50 ($31K) on 2018-09-24, disclosed to the SEC on 2018-09-26.
Scheduled sale ($31k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ACRX | SELL | 2017-10-03 | $108K | — | Filing → |